Takeda announced plans to lay off nearly 250 workers at its Cambridge, Massachusetts site, beginning in July, after a board-approved cost-saving plan approved March 25. The workforce reduction is part of a broader multiyear restructuring expected to generate about $1.25 billion in annual savings by 2028. The filing indicates that most of the Massachusetts roles are located at Takeda’s 500 Kendall St. address, with additional job cuts potentially affecting 387 roles in other states. Takeda said notifications are tied to the timeline of the restructuring plan rather than immediate termination for all impacted workers. The announcement follows other major Takeda restructuring actions in recent years, including reductions associated with shifts in R&D priorities and loss of exclusivity for core products. The scale of the cuts reinforces how large biopharma employers are continuing to rebalance cost structures in a tougher capital and pipeline environment. For the industry, the move signals that workforce optimization is still a near-term lever—particularly at high-cost manufacturing and R&D hubs—while companies wait for later clinical and regulatory catalysts.